EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide1. Chemotherapies such as the topoisomerase II inhibitor (TopoIIi) etoposide effectively reduce disease in a minority of NSCLC patients2,3; therefore, alternative drug targets, including epigenetic enzymes, are...

Full description

Bibliographic Details
Main Authors: Fillmore, Christine M., Xu, Chunxiao, Desai, Pooja T., Berry, Joanne M., Rowbotham, Samuel P., Lin, Yi-Jang, Zhang, Haikuo, Marquez, Victor E., Hammerman, Peter S., Wong, Kwok-Kin, Kim, Carla F.
Format: Online
Language:English
Published: 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393352/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393352/

Similar Items